Skip to main content
BRAIN Biotech AG logo

BRAIN Biotech AG — Investor Relations & Filings

Ticker · BNN ISIN · DE0005203947 LEI · 391200JKPVHLD6JLZ107 F Professional, scientific and technical activities
Open in API
Filings indexed 368 across all filing types
Latest filing 2021-09-15 Capital/Financing Update
Country DE Germany
Listing F BNN

About BRAIN Biotech AG

https://www.brain-biotech.com/

BRAIN Biotech AG is an industrial biotechnology company specializing in the discovery, development, and production of specialty enzymes, high-performance microorganisms, and bioactive compounds. The company provides tailor-made biosolutions and contract research and development (R&D) services to partners in the food, chemical, and life sciences sectors. Core competencies include enzyme technology, microbial strain development, and bioprocess development. By leveraging an advanced technology portfolio, which includes proprietary platforms for enzyme discovery and genome editing, the company enables its partners to create more sustainable and efficient industrial products and processes, contributing to the bioeconomy.

Recent filings

Filing Released Lang Actions
BRAIN Biotech AG resolves on a cash capital increase from authorised capital
Capital/Financing Update Classification · 98% confidence The document is a news release dated September 15, 2021, announcing that BRAIN Biotech AG has resolved to increase its share capital through the issuance of new shares for cash contribution, explicitly mentioning the exclusion of statutory subscription rights and the intended use of proceeds. This action directly relates to the company's capital structure and fundraising activities. This aligns perfectly with the definition of 'Capital/Financing Update' (Code: CAP). Although it mentions DGAP (a distribution service), the content is the primary announcement of the capital increase itself, not just an announcement that a report is attached (which would suggest RPA or RNS).
2021-09-15 English
BRAIN Biotech AG resolves on a 10% cash capital increase from authorised capital with exclusion of statutory subscription rights.
Capital/Financing Update Classification · 99% confidence The document is an 'Ad-hoc' announcement dated 15 September 2021, explicitly stating that BRAIN Biotech AG 'resolves on a 10% cash capital increase from authorised capital with exclusion of statutory subscription rights.' It details the issuance of new shares, targeted proceeds, intended use of funds, and the private placement process. This content directly relates to fundraising, financing activities, and changes to the capital structure. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple announcement of a report (RPA).
2021-09-15 English
Capital Markets Day BRAIN Biotech AG: Focus on BEC Technology and its Transformational Potential
Regulatory Filings Classification · 100% confidence The document is titled 'Capital Markets Day BRAIN Biotech AG: Focus on BEC Technology and its Transformational Potential' and explicitly states that the information was shared during a 'Capital Markets Day'. A Capital Markets Day (CMD) is an event where management presents strategic updates, technology focus, and future outlook to investors. This type of presentation material, focusing on strategy and technology potential, aligns best with an Investor Presentation (IP). Although it is distributed as a news release via DGAP, the core content is the presentation material from the CMD, not a formal regulatory filing like a 10-K or an earnings release (ER). It is more detailed than a simple Fund Factsheet (FS) and is not a transcript (CT) or a formal report (AR/IR).
2021-09-03 English
Declaration of Voting Results & Voting Rights Announcements 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Notification of Major Holdings' under German securities law (WpHG). It reports changes in the percentage of voting rights held by a legal entity (Montagu Private Equity LLP) in BRAIN Biotech AG, specifically noting a change in attribution due to a declaration of independence. This directly corresponds to the definition of reporting changes in significant share ownership levels, which aligns best with the Major Shareholding Notification category (MRQ). Although it mentions 'Voting Rights Announcements' in the header, the content is a formal notification of a change in holding percentage, which is the core function of an MRQ filing.
2021-09-03 English
Declaration of Voting Results & Voting Rights Announcements 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Notification of Major Holdings' under Section 1. It details changes in the percentage of voting rights held by a specific entity (Montagu Private Equity LLP and its chain) in BRAIN Biotech AG, referencing German Securities Trading Act (WpHG) sections (Art. 40, Sec. 33, 34, 35, 38). This content directly corresponds to the definition of reporting changes in significant share ownership thresholds. The filing type 'Major Shareholding Notification' (MRQ) is the most appropriate classification for notifications regarding changes in significant share ownership levels (crossing thresholds), which is exactly what this document reports, despite the header mentioning 'Voting Rights Announcements' (which is often a broader category used by dissemination services like DGAP for these specific filings).
2021-09-03 English
BRAIN Biotech AG: BRAIN appoints University of Leiden as partner for BEC-Enabled production strain development
Regulatory Filings Classification · 100% confidence The document is a press release dated September 1, 2021, announcing a new partnership between BRAIN Biotech AG and the University of Leiden for developing a production strain using BRAIN's proprietary technology (BEC). It details a strategic alliance and technological collaboration. This type of announcement, which is a corporate news release about a business development (alliance/partnership) and does not fit neatly into specific financial reporting categories (like 10-K, ER, or IR), is best classified as a general Regulatory Filing or Corporate News announcement. Since 'Regulatory Filings (RNS)' is defined as 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories,' this is the most appropriate classification. It is not a formal financial report, earnings release, or management discussion.
2021-09-01 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.